| Quarterly Financials | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 58 | 34 | 30 | 20 | 21 | 18 | 13 | 15 | 27 | 19 | 8 | 8 | 15 |
| Expenses | 137 | 126 | 113 | 117 | 122 | 110 | 116 | 89 | 80 | 62 | 74 | 77 | 80 |
| EBITDA | -79 | -92 | -83 | -96 | -101 | -92 | -103 | -74 | -53 | -43 | -66 | -69 | -65 |
| Operating Profit % | -188 % | -427 % | -432 % | -740 % | -639 % | -555 % | -800 % | -494 % | -196 % | -540 % | -836 % | -817 % | -506 % |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 | 12 |
| Profit Before Tax | -82 | -95 | -86 | -100 | -105 | -96 | -107 | -79 | -61 | -52 | -76 | -80 | 1,761 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | -0 |
| Net Profit | -82 | -95 | -86 | -100 | -106 | -96 | -107 | -80 | -60 | -52 | -76 | -80 | 1,761 |
| EPS in ₹ | -2.55 | -2.94 | -2.66 | -3.07 | -3.26 | -2.96 | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 |
Sun Pharma Advanced Research Co
Sun Pharma Advanced Research Co
208.43
-4.74
(-2.22%)
Market Cap
6,763.54 Cr
PE Ratio
4.45
Volume
9,53,652.00
Day High - Low
215.39 - 207.65
52W High-Low
289.00 - 108.00
Key Fundamentals
Market Cap
6,763.54 Cr
EPS
47.86
PE Ratio
4.45
PB Ratio
5.16
Book Value
41.26
EBITDA
1,609.70
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
116.01
Debt to Equity
0.74
Analyst Rating and Forecast
- By Refinitiv from2 analysts
Actual
Company News
View All News
Sun Pharma Advanced Research Company Ltd received requests from promoter group members to reclassify their shares to the public category, impacting holding patterns.
SPARC files BRSR for FY 2025-26
Jul 17, 2026
Jul 17, 2026Sun Pharma Advanced Research Company Ltd filed its BRSR for FY 2025-26. The report details ESG initiatives, workforce data, and environmental metrics.
SPARC FY26 results, PRV saleJul 17, 2026
Jul 17, 2026Sun Pharma Advanced Research Co reported a net profit of ₹1,55,320.43 lakh for FY26, driven by the sale of a Priority Review Voucher for USD 195 million.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,001.10 | #1 4,80,130.92 | 41.48 | #1 61,673.90 | 12.69 | #1 11,565 | 25.80 | 70.23 | |
7,835.00 | 2,07,994.63 | 80.57 | 11,067.00 | 13.95 | 2,568 | 13.44 | 78.93 | |
4,872.10 | 1,85,319.02 | 86.77 | 13,886.20 | 20.34 | 2,138 | -26.91 | 52.19 | |
1,466.40 | 1,18,462.44 | 35.47 | 29,044.60 | 2.24 | 3,870 | -39.18 | 60.03 | |
1,115.10 | 1,12,205.15 | 21.85 | 27,657.90 | 17.64 | 5,026 | 7.82 | 49.15 | |
2,421.20 | 1,10,705.14 | #1 20.92 | 29,038.90 | #1 26.75 | 5,356 | 87.72 | 50.28 | |
2,575.90 | 1,06,383.63 | 55.24 | 14,636.40 | 14.85 | 1,938 | 31.75 | 56.18 | |
1,781.30 | 96,164.65 | 88.29 | 6,867.80 | 22.01 | 890 | #1 123.93 | 79.83 | |
1,144.80 | 95,552.92 | 29.97 | 35,058.60 | 3.90 | 4,158 | -69.10 | 27.15 | |
1,576.30 | 90,696.82 | 26.38 | 33,384.70 | 3.21 | 3,376 | 1.99 | 56.67 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
2,468.07 %
Net Income Growth
-553.49 %
Cash Flow Change
33.73 %
ROE
-26.52 %
ROCE
-87.01 %
EBITDA Margin (Avg.)
-119.49 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 830 | 515 | 336 | 2,171 |
| Fixed Assets | 106 | 108 | 99 | 85 |
| Current Assets | 455 | 269 | 26 | 1,862 |
| Capital Work in Progress | 27 | 44 | 54 | 72 |
| Investments | 291 | 2 | 0 | 0 |
| Other Assets | 407 | 362 | 183 | 2,014 |
| Total Equity & Liabilities | 830 | 515 | 336 | 2,171 |
| Current Liabilities | 179 | 265 | 374 | 754 |
| Non Current Liabilities | 138 | 124 | 178 | 78 |
| Total Equity | 513 | 126 | -217 | 1,339 |
| Reserve & Surplus | 480 | 93 | -249 | 1,306 |
| Share Capital | 33 | 33 | 33 | 33 |
Cash Flow
| Cash Flow | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | -1 | 5 | -3 | -1 |
| Investing Activities | -548 | 392 | 158 | -23 |
| Operating Activities | -69 | -429 | -360 | -239 |
| Financing Activities | 617 | 42 | 199 | 261 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | May 2026 | Jun 2026 |
| Promoter | 68.46 % | 68.46 % | 68.10 % | 68.10 % | 69.09 % | 69.09 % | 69.09 % | 68.22 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % | 65.67 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.30 % | 3.23 % | 2.64 % | 2.15 % | 2.23 % | 1.45 % | 1.47 % | 1.76 % | 2.04 % | 2.04 % | 2.47 % | 3.90 % |
| DIIs | 0.01 % | 0.02 % | 0.02 % | 0.02 % | 0.24 % | 0.24 % | 0.24 % | 0.93 % | 0.78 % | 0.78 % | 0.23 % | 0.81 % | 0.82 % | 0.18 % | 0.23 % | 0.64 % | 1.13 % | 0.97 % | 1.05 % | 0.78 % | 0.88 % | 0.10 % | 0.09 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 18.08 % | 18.00 % | 16.91 % | 16.94 % | 14.73 % | 16.45 % | 15.70 % | 16.00 % | 16.18 % | 16.13 % | 15.90 % | 16.09 % | 16.11 % | 18.91 % | 19.20 % | 18.89 % | 18.99 % | 19.15 % | 18.94 % | 19.20 % | 16.81 % | 19.13 % | 18.57 % |
| Others | 13.45 % | 13.52 % | 14.97 % | 14.94 % | 15.94 % | 14.22 % | 14.97 % | 14.85 % | 17.37 % | 17.42 % | 18.20 % | 14.13 % | 14.17 % | 12.60 % | 12.75 % | 12.58 % | 12.76 % | 12.73 % | 12.59 % | 12.30 % | 14.60 % | 12.63 % | 11.76 % |
| No of Share Holders | 0 | 99,454 | 1,10,301 | 94,834 | 95,039 | 93,097 | 94,494 | 93,718 | 96,337 | 1,00,807 | 1,01,433 | 1,03,990 | 1,02,743 | 1,25,184 | 1,28,205 | 1,31,034 | 1,42,864 | 1,40,724 | 1,36,997 | 1,44,810 | 1,40,625 | 1,37,538 | 1,41,957 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 10 Aug 2026 |  Annual General Meeting | NA | 10 Aug 2026 | 239.15 | 213.00 |
| 12 Aug 2024 | Annual General Meeting | NA | 12 Aug 2024 | 251.25 | 218.80 |
| 04 Nov 2024 |  Quarterly Result Announcement | NA | 04 Nov 2024 | 207.65 | 216.10 |
| 10 Feb 2025 | Quarterly Result Announcement | NA | 10 Feb 2025 | 157.60 | 158.85 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 140.85 | 161.20 |
| 04 Aug 2025 | Quarterly Result Announcement | NA | 04 Aug 2025 | 151.65 | 149.45 |
| 12 Aug 2025 | Annual General Meeting | NA | 12 Aug 2025 | 157.15 | 142.35 |
| 10 Nov 2025 | Quarterly Result Announcement | NA | 10 Nov 2025 | 137.05 | 133.30 |
| 09 Feb 2026 |  Extraordinary General Meeting | NA | 09 Feb 2026 | 135.45 | 139.05 |
| 09 Feb 2026 | Quarterly Result Announcement | NA | 09 Feb 2026 | 133.30 | 139.05 |
| 18 May 2026 | Quarterly Result Announcement | NA | 18 May 2026 | 172.85 | 163.60 |
Announcements
Intimation For Receipt Of Requests For Reclassification Of Shareholder Category3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2026
Jul 17, 2026Business Responsibility and Sustainability Reporting (BRSR)Jul 16, 2026
Jul 16, 2026Notice Of 21St Annual General Meeting To Be Held On August 10 2026 Along With The Annual Report For FY 26Jul 16, 2026
Jul 16, 2026Reg. 34 (1) Annual Report.Jul 16, 2026
Jul 16, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateJul 13, 2026
Jul 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 09, 2026
Jul 09, 2026Intimation Regarding 21St Annual General Meeting Of The CompanyJul 06, 2026
Jul 06, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 06, 2026
Jul 06, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJun 26, 2026
Jun 26, 2026Termination Of License Agreement With CMS Bridging DMCCJun 25, 2026
Jun 25, 2026Closure of Trading WindowJun 24, 2026
Jun 24, 2026Statutory Auditors Certificate In Terms Of Regulation 169(5) Of SEBI ICDRA Regulations 2018May 25, 2026
May 25, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 20, 2026
May 20, 2026Update On PDP-716 NDAMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-AllotmentMay 19, 2026
May 19, 2026Audited Financial Results For The Quarter And Year Ended March 31 2026May 18, 2026
May 18, 2026Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Financial Year Ended March 31 2026May 11, 2026
May 11, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 30, 2026
Apr 30, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Apr 06, 2026Announcement under Regulation 30 (LODR)-Change in ManagementApr 03, 2026
Apr 03, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMar 27, 2026
Mar 27, 2026Clarification Regarding Increase In VolumeMar 27, 2026
Mar 27, 2026Clarification sought from Sun Pharma Advanced Research Company LtdMar 27, 2026
Mar 27, 2026Closure of Trading WindowMar 26, 2026
Mar 26, 2026Addendum To The Valuation Report Issued On January 14 2026Feb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 10, 2026
Feb 10, 2026Shareholder Meeting / Postal Ballot-Outcome of EGMFeb 09, 2026
Feb 09, 2026Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 09, 2026
Feb 09, 2026Board Meeting Outcome for For Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 09, 2026
Feb 09, 2026Board Meeting Intimation for Approval Of Unaudited Financial Results For Quarter And Nine Months Ended December 31 2025Feb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2026
Feb 03, 2026Clarification Regarding Increase In VolumeFeb 02, 2026
Feb 02, 2026Clarification sought from Sun Pharma Advanced Research Company LtdFeb 02, 2026
Feb 02, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 30, 2026
Jan 30, 2026Corrigendum To The Notice Of Extra Ordinary General Meeting Of The Company Scheduled To Be Held On Monday February 09 2026Jan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 17, 2026
Jan 17, 2026Notice Of Extra Ordinary General Meeting Of Sun Pharma Advanced Research Company LimitedJan 16, 2026
Jan 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 16, 2026
Jan 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 15, 2026
Jan 15, 2026Board Meeting Outcome for Outcome Of The Board Meeting Held On January 14 2026Jan 14, 2026
Jan 14, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJan 13, 2026
Jan 13, 2026Board Meeting Intimation for Approval Of Proposal For Raising Funds By The Company Through Preferential Issue Of Securities Including Convertible Warrants.Jan 11, 2026
Jan 11, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJan 08, 2026
Jan 08, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2026
Jan 06, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 31, 2025
Dec 31, 2025Closure of Trading WindowDec 29, 2025
Dec 29, 2025Clarification Regarding Increase In The VolumeDec 03, 2025
Dec 03, 2025Clarification sought from Sun Pharma Advanced Research Company LtdDec 03, 2025
Dec 03, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Motilal Oswal BSE 1000 Index Fund Direct-Growth | 0.01% | -2 | 0.00% | 0.00% | |
 Angel One Nifty Total Market Index Fund Direct-Growth | 0.01% | 0 | 0.00% | 0.00% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.14% | 0 | 0.00% | 0.00% | |
Bandhan Nifty Total Market Index Fund Direct-Growth | 0.01% | 0 | 0.00% | 0.00% | |
 Groww Nifty Total Market Index Fund Direct-Growth | 0.01% | 0 | 0.00% | 0.00% | |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth | 0.00% | 0 | 0.00% | 0.00% | |
 Mirae Asset Nifty Total Market Index Fund Direct-Growth | 0.01% | 0 | 0.00% | 0.00% | |
Motilal Oswal Nifty Microcap 250 Index Fund Direct-Growth | 0.25% | 0 | 0.00% | 0.01% |
Technical Indicators
RSI(14)
Neutral 39.22
ATR(14)
Less Volatile 11.60
STOCH(9,6)
Oversold 6.80
STOCH RSI(14)
Oversold 4.45
MACD(12,26)
Bearish -5.60
ADX(14)
Strong Trend 27.45
UO(9)
Bearish 32.29
ROC(12)
Downtrend And Accelerating -17.83
WillR(14)
Oversold -92.12
About Sun Pharma Advanced Research Co
Sun Pharma Advanced Research Company Ltd. (SPARC) is an India-based clinical-stage biopharmaceutical company focused on developing new drugs and delivery systems. It specializes in creating therapeutics in oncology, neurology, and immunology. SPARC's key projects include vodobatinib for chronic myelogenous leukemia and neurodegenerative diseases, an anti-MUC-1 antibody-drug conjugate for multiple cancers,...more
Website
Chairperson NameDilip S Shanghvi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
